Literature DB >> 20551327

Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

Yaowu He1, Andreas Wortmann, Les J Burke, Janet C Reid, Mark N Adams, Ibtissam Abdul-Jabbar, James P Quigley, Richard Leduc, Daniel Kirchhofer, John D Hooper.   

Abstract

CUB-domain-containing protein 1 (CDCP1) is an integral membrane glycoprotein with potential as a marker and therapeutic target for a number of cancers. Here we examine mechanisms regulating cellular processing of CDCP1. By analyzing cell lines exclusively passaged non-enzymatically and through use of a panel of protease inhibitors, we demonstrate that full-length 135 kDa CDCP1 is post-translationally processed in a range of cell lines by a mechanism involving serine protease activity, generating a C-terminal 70-kDa fragment. Immunopurification and N-terminal sequencing of this cell-retained fragment and detailed mutagenesis, show that proteolytic processing of CDCP1 occurs at two sites, Arg-368 and Lys-369. We show that the serine protease matriptase is an efficient, but not essential, cellular processor of CDCP1 at Arg-368. Importantly, we also demonstrate that proteolysis induces tyrosine phosphorylation of 70-kDa CDCP1 and recruitment of Src and PKCdelta to this fragment. In addition, Western blot and mass spectroscopy analyses show that an N-terminal 65-kDa CDCP1 ectodomain is shed intact from the cell surface. These data provide new insights into mechanisms regulating CDCP1 and suggest that the biological role of this protein and, potentially, its function in cancer, may be mediated by both 70-kDa cell retained and 65-kDa shed fragments, as well as the full-length 135-kDa protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551327      PMCID: PMC2924022          DOI: 10.1074/jbc.M109.096453

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes.

Authors:  J D Hooper; J A Clements; J P Quigley; T M Antalis
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.

Authors:  Danislav S Spassov; Frederick L Baehner; Ching Hang Wong; Stephen McDonough; Mark M Moasser
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

3.  Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis.

Authors:  Karin List; Christian C Haudenschild; Roman Szabo; WanJun Chen; Sharon M Wahl; William Swaim; Lars H Engelholm; Niels Behrendt; Thomas H Bugge
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

4.  Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS.

Authors:  Magali André; Jean-Pierre Le Caer; Céline Greco; Sébastien Planchon; Wassim El Nemer; Claude Boucheix; Eric Rubinstein; Julia Chamot-Rooke; François Le Naour
Journal:  Proteomics       Date:  2006-03       Impact factor: 3.984

5.  Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.

Authors:  Jian-Ai Xuan; Doug Schneider; Pam Toy; Rick Lin; Alicia Newton; Ying Zhu; Silke Finster; David Vogel; Bob Mintzer; Harald Dinter; David Light; Renate Parry; Mark Polokoff; Marc Whitlow; Qingyu Wu; Gordon Parry
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

6.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

Review 7.  The cell surface glycoprotein CDCP1 in cancer--insights, opportunities, and challenges.

Authors:  Andreas Wortmann; Yaowu He; Elena I Deryugina; James P Quigley; John D Hooper
Journal:  IUBMB Life       Date:  2009-07       Impact factor: 3.885

8.  Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10.

Authors:  Cristina I Caescu; Grace R Jeschke; Benjamin E Turk
Journal:  Biochem J       Date:  2009-10-23       Impact factor: 3.857

9.  CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.

Authors:  Takamasa Uekita; Lin Jia; Mako Narisawa-Saito; Jun Yokota; Tohru Kiyono; Ryuichi Sakai
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

10.  Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides.

Authors:  François Béliveau; Antoine Désilets; Richard Leduc
Journal:  FEBS J       Date:  2009-03-03       Impact factor: 5.542

View more
  40 in total

1.  CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.

Authors:  H J Wright; J Arulmoli; M Motazedi; L J Nelson; F S Heinemann; L A Flanagan; O V Razorenova
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.

Authors:  Ying Dong; Yaowu He; Leonore de Boer; M Sharon Stack; John W Lumley; Judith A Clements; John D Hooper
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

3.  Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state.

Authors:  Danislav S Spassov; Ching H Wong; Mark M Moasser
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

4.  The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.

Authors:  C H Benes; G Poulogiannis; L C Cantley; S P Soltoff
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

5.  Design and synthesis of potent, selective inhibitors of matriptase.

Authors:  Eloïc Colombo; Antoine Désilets; Dominic Duchêne; Félix Chagnon; Rafael Najmanovich; Richard Leduc; Eric Marsault
Journal:  ACS Med Chem Lett       Date:  2012-04-11       Impact factor: 4.345

Review 6.  The role of type II transmembrane serine protease-mediated signaling in cancer.

Authors:  Lauren M Tanabe; Karin List
Journal:  FEBS J       Date:  2016-12-24       Impact factor: 5.542

7.  Evaluation of antibodies directed against human protease-activated receptor-2.

Authors:  Mark N Adams; Charles N Pagel; Eleanor J Mackie; John D Hooper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-31       Impact factor: 3.000

8.  Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.

Authors:  Danislav S Spassov; Ching Hang Wong; Sunny Y Wong; Jeremy F Reiter; Mark M Moasser
Journal:  Cancer Res       Date:  2012-12-12       Impact factor: 12.701

9.  Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.

Authors:  Brooke M Emerling; Cyril H Benes; George Poulogiannis; Eric L Bell; Kevin Courtney; Hui Liu; Rayman Choo-Wing; Gary Bellinger; Kazumi S Tsukazawa; Victoria Brown; Sabina Signoretti; Stephen P Soltoff; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-01       Impact factor: 11.205

10.  In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

Authors:  B Casar; I Rimann; H Kato; S J Shattil; J P Quigley; E I Deryugina
Journal:  Oncogene       Date:  2012-12-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.